While BRAF/MEK and PI3K/AKT pathway inhibitors represent an intriguing therapeutic option for patients with metastatic melanoma, the success of these therapeutics is reduced by the development of acquired resistance via MSC-dependent mechanisms. This evidence concerns the gene AKT1 and metastatic melanoma.